Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12689886 | 0.89 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL4546336 | 0.88 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL4546342 | 0.87 | TRPV1 (0.85) | TRPV1 | |
| SCHEMBL4870565 | 0.87 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL4876038 | 0.86 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL1250898 | 0.85 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL13743067 | 0.85 | TRPV1 (0.80) | TRPV1 | |
| SCHEMBL4865985 | 0.84 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL4872431 | 0.84 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL4865046 | 0.83 | TRPV1 (0.78) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017954-A1 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation (US) | 2025-01-16 | — | — | US | claimed |
| EP-4433045-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | KINDRA CORPORATION (US) | 2024-09-25 | — | — | EP | claimed |
| CN-118510501-A | Formulations and methods for treating climacteric symptoms | 金卓拉公司 | 2024-08-16 | — | — | CN | claimed |
| WO-2023091628-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) | 2023-05-25 | — | — | WO | claimed |
| JP-2007523865-A | — | — | 2007-08-23 | — | — | JP | claimed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | claimed |
| EP-1646621-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2006-04-19 | — | — | EP | claimed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005007642-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2005-01-27 | — | — | WO | claimed |
| US-20050009841-A1 | Novel amides useful for treating pain | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | claimed |
| US-20250017954-A1 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | HABBOUSHE JOSEPH (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4472615-A1 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Oculis Operations Sàrl (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-20240390515-A1 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Oculis Operations Sàrl (CH) | 2024-11-28 | — | — | US | disclosed |
| EP-4433045-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | KINDRA CORPORATION (US) | 2024-09-25 | — | — | EP | disclosed |
| US-7348343-B2 | Amides useful for treating pain | ABBOTT LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070010557-A1 | Novel amides useful for treating pain | ABBVIE INC. | 2007-01-11 | — | — | US | disclosed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009841-A1 | Novel amides useful for treating pain | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009841-A1 | Novel amides useful for treating pain | OPRL1, OPRK1, FAAH2 | TRPV1 6/4885CA12 1713/4885CA1 842/4885 |
| US-20240390515-A1 | MULTIDOSE OPHTHALMIC COMPOSITIONS | SORBS1, PDCD6, PDCD2L | TRPV1 3161/4885CA12 3001/4885CA1 4094/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | TRPV1 1/4885CA12 3855/4885CA1 2290/4885 |
| US-20070010557-A1 | Novel amides useful for treating pain | OPRL1, PDE6B, PDE6G | TRPV1 8/4885CA12 2843/4885CA1 1046/4885 |
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | CNR2, TRPV1, CNR1 | TRPV1 2/4885CA12 906/4885CA1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.